Skip to main content

Main menu

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 Articles
  • Authors
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
  • CMA Members
    • Overview for members
    • Earn CPD Credits
    • Print copies of CMAJ
  • Subscribers
    • General information
    • View prices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2022
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN

User menu

Search

  • Advanced search
CMAJ
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN
CMAJ

Advanced Search

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 Articles
  • Authors
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
  • CMA Members
    • Overview for members
    • Earn CPD Credits
    • Print copies of CMAJ
  • Subscribers
    • General information
    • View prices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2022
  • Visit CMAJ on Facebook
  • Follow CMAJ on Twitter
  • Follow CMAJ on Pinterest
  • Follow CMAJ on Youtube
  • Follow CMAJ on Instagram
News

Germany clambers aboard translational research bandwagon

Kai Kupferschmidt
CMAJ March 08, 2011 183 (4) E219-E220; DOI: https://doi.org/10.1503/cmaj.109-3795
Kai Kupferschmidt
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Responses
  • Metrics
  • PDF
Loading

It’s almost as if a slow wave is overtaking the medical research enterprise in the western world.

Scant weeks after the National Institutes of Health in the United States indicated that it will reform its programming to speed the delivery of new drugs and therapies (www.cmaj.ca/cgi/doi/10.1503/cmaj.109-3777), the government of Germany has announced a new health program aimed at shortening the time it takes for the results of basic and clinical research to become part of regular medical care.

“We want to get new treatments to the patients as fast as possible,” Annette Schavan, Germany’s minister of research, told a press conference at which she and Health Minister Philipp Rösler sketched the new program’s priorities over the course of the next eight years.

The program focuses on studying common diseases such as cancer, diabetes and Alzheimer disease, as well as cardiovascular and infectious diseases. To that end, the government will spend €5.5 billion on health research between 2011–2014. That will include spending on personalized medicine, prevention, nutrition and health care delivery research.

The “centrepiece of the program,” Schavan said, will be the creation of four more national health research centres. She hopes those will make translation — the application of new medical knowledge in the clinic or hospital — faster and more effective. It is also hoped the centres will make more efficient use of funds, pool resources to enable large studies and attract top-flight international talent.

Two national centres, the German Centre for Neurodegenerative Diseases and the National Centre for Diabetes Research, have already opened. They’ll be joined this year by others dedicated to research on cardiovascular diseases, infectious diseases, lung diseases and cancer.

It constitutes a seismic shift in the structure and organization of German health research. Traditionally, biomedical research has been done either by universities and university clinics, or by independent research institutes typically funded by societies.

Figure

“We want to get new treatments to the patients as fast as possible,” Annette Schavan, Germany’s minister of research, told a press conference while announcing that her government will spend €5.5 billion on health research between 2011–2014.

Image courtesy of Reuters/Thomas Peter

The new centres, though, will be collaborative ventures between universities and research institutes, Schavan said. “We want to bring the best people in a field together.”

There has been some grumbling among a few researchers in response to the government initiative, largely around which researchers were chosen, or not chosen, to be part of a national centre.

In the case of the National Centre for Infectious Diseases, for example, several have expressed surprise that neither tuberculosis researcher Stefan Kaufmann nor nosocomial infection expert Dr. Petra Gastmeier were selected. “Some researchers, that one would have liked to be in there, did not make it,” says Dr. Dieter Bitter-Suermann, president of the German Medical Faculty Association and head of research at the Hannover Medical School, which is part of the infectious diseases institute.

Others query the priorities of the infectious diseases institute. “Viral diseases, even exotic ones are very well represented in the centre. But sepsis, which kills 144 people every day, is not,” says Dr. Konrad Reinhart, director of the department of anesthesiology and intensive care medicine at the University Hospital of the Friedrich-Schiller University of Jena and coordinator of Competence Network Sepsis, a network of experts conducting clinical and experimental sepsis research.

“Connecting the best researchers in a field is a good idea,” he says. “But if important diseases such as sepsis are not included, then that will be a big problem in the long run,” says Reinhart, who along with Gastmeier penned a letter to the government criticizing the omission of sepsis and hospital-acquired infections in the infectious diseases institute’s research program.

Other contentious issues involve the funding, structure and organization of the institutes. As the German government is prohibited from directly funding universities, the €500 million that is ticketed for the six centres over the next four years will be funnelled through the Helmholtz Society, a union of 16 research centres with a budget of €3 billion annually, 90% of which comes from the federal government.

Critics charge that the arrangement gives the Helmholtz Society too much power. “In the first two centres, the Helmholtz Society is in effect like the spider in the middle of the net,” Bitter-Suermann says. Some fear that amounts to institutes under the wing of the Helmholtz Society being able to essentially buy access to patients and patient data, which would be invaluable in recruiting participants for clinical trials.

Because of such criticism, three of the new centres — for cardiovascular, infectious and lung diseases — will have structures in which universities will be given more input into how available monies will be spent.

It means that the six national health research centres will fall into two camps: those centrally organized and under the wing of the Helmholtz Society, and three in which universities will have more influence. “It will be very interesting to see how these two groups do,” Bitter-Suermann says.

Many predict glowing outcomes and impacts. “This is a huge change and a huge chance,” says Dr. Otmar Wiestler, head of the German Cancer Research Centre in Heidelberg, which will lead the new centre for translational cancer research.

But not all the centres will be equally effective immediately, he adds. “At the moment, it takes 15 years to go from a medical discovery to it being part of patient care. We need to reduce that to 5 to 10 years.”

The pooling of talent and resources should aid in that, says Dr. Simone Fulda, professor for experimental tumour research at the University of Frankfurt and a member of the translational cancer centre. “We will only be able to solve the big challenges in medicine if we get all the experts to work together.”

PreviousNext
Back to top

In this issue

Canadian Medical Association Journal: 183 (4)
CMAJ
Vol. 183, Issue 4
8 Mar 2011
  • Table of Contents
  • Index by author

Article tools

Respond to this article
Print
Download PDF
Article Alerts
To sign up for email alerts or to access your current email alerts, enter your email address below:
Email Article

Thank you for your interest in spreading the word on CMAJ.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Germany clambers aboard translational research bandwagon
(Your Name) has sent you a message from CMAJ
(Your Name) thought you would like to see the CMAJ web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Germany clambers aboard translational research bandwagon
Kai Kupferschmidt
CMAJ Mar 2011, 183 (4) E219-E220; DOI: 10.1503/cmaj.109-3795

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
‍ Request Permissions
Share
Germany clambers aboard translational research bandwagon
Kai Kupferschmidt
CMAJ Mar 2011, 183 (4) E219-E220; DOI: 10.1503/cmaj.109-3795
Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
  • Responses
  • Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • What the U.S. overturning Roe v. Wade means for Canada
  • Is one-way masking enough?
  • XE, XD & XF: what to know about the Omicron hybrid variants
Show more News

Similar Articles

 

View Latest Classified Ads

Content

  • Current issue
  • Past issues
  • Collections
  • Sections
  • Blog
  • Podcasts
  • Alerts
  • RSS
  • Early releases

Information for

  • Advertisers
  • Authors
  • Reviewers
  • CMA Members
  • Media
  • Reprint requests
  • Subscribers

About

  • General Information
  • Journal staff
  • Editorial Board
  • Advisory Panels
  • Governance Council
  • Journal Oversight
  • Careers
  • Contact
  • Copyright and Permissions
  • Accessibiity
  • CMA Civility Standards
CMAJ Group

Copyright 2022, CMA Impact Inc. or its licensors. All rights reserved. ISSN 1488-2329 (e) 0820-3946 (p)

All editorial matter in CMAJ represents the opinions of the authors and not necessarily those of the Canadian Medical Association or its subsidiaries.

To receive any of these resources in an accessible format, please contact us at CMAJ Group, 500-1410 Blair Towers Place, Ottawa ON, K1J 9B9; p: 1-888-855-2555; e: cmajgroup@cmaj.ca

Powered by HighWire